Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Methods A systematic search was conducted using the Medline® and Embase® databases
up to 30 June 2017 employing specific medical subject heading terms. Additionally, the …

Objectives Real-world evidence on effectiveness of switching to biosimila r etanercept is
scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) …

Background Biosimilars have been used for 15 years in the European Union (EU), and have
been shown to reduce costs and increase access to important biological medicines. In spite …

Background Adalimumab is used to treat several inflammatory diseases, including plaque
psoriasis. GP2017 is a proposed adalimumab biosimilar. Objectives To assess the impact of …

Objective The 24‐week equivalent efficacy and comparable safety results of the biosimilar
SB5 and reference adalimumab (ADA) from the phase III randomized study in patients with …

Etanercept was the first specific anticytokine therapy approved for the treatment of
rheumatoid arthritis (RA). Its clinical efficacy and safety has been demonstrated by several …

The act of nonmedical switching, defined as switching stable patients who are generally
doing well with their current therapy from an originator biologic to its biosimilar, has been …

Compared with the original approved biological drug on which it is based, a biosimilar has
highly similar physicochemical characteristics and biological activity, as well as equivalent …

Abstract The World Health Organization (WHO) guidelines on evaluation of similar
biotherapeutic products (SBPs; also called biosimilars) were adopted by the WHO Expert …